This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weber, M. A. Articles by Luther, R. Search for Related Content PubMed PubMed Citation Articles by Weber, M. A. Articles by Luther, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Hazardous Substances DB HYDROCHLOROTHIAZIDE

Circulation, Vol 81, 1768-1774, Copyright © 1990 by American Heart Association

ARTICLES

Assessment of renin dependency of hypertension with a dipeptide renin inhibitor

MA Weber, JM Neutel, I Essinger, HN Glassman, RS Boger and R Luther
Hypertension Center, Veterans Administration Medical Center, Long Beach, CA 90822.

To evaluate the participation of the renin-angiotensin system in sustaining hypertension, we administered the specific dipeptide renin inhibitor enalkiren (A-64662) to 18 patients with essential hypertension. Ascending intravenous bolus doses (0.03, 0.1, 0.3, and 1.0 mg/kg) of the inhibitor were each given at 45-minute intervals to patients maintained on an ad libitum sodium diet who were studied while in bed in the semirecumbent posture. Enalkiren produced marked decreases in plasma renin activity (PRA) that were still evident 8 hours after completion of dosing. Systolic and diastolic blood pressures were decreased in a dose-dependent fashion without an effect on heart rate. Repetition of this procedure after patients were subjected to sodium depletion by 1 week of thiazide treatment produced amplified decreases in blood pressure. Despite the short plasma half- life of the inhibitor, these blood pressure-lowering effects were sustained for 4-8 hours when compared with parallel placebo administration in the same patients. Both the baseline PRA and the inhibitor-induced changes in PRA correlated significantly with blood pressure changes during the unstimulated and the sodium-depleted studies. However, effects of the inhibitor on diastolic blood pressure in the latter study correlated most closely with actual increases in renin produced by diuretic pretreatment. Thus, this specific renin inhibitor has demonstrated the dependency of blood pressure on the renin-angiotensin system even during basal conditions in hypertensive patients. Moreover, renin response to sodium depletion appears to be an attribute that additionally characterizes individual hypertensive patients.

This article has been cited by other articles:

				A. Stanton, C. Jensen, J. Nussberger, and E. O'Brien Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren Hypertension, December 1, 2003; 42(6): 1137 - 1143. [Abstract] [Full Text] [PDF]

				A. Stanton Review: Potential of renin inhibition in cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, March 1, 2003; 4(1): 6 - 10. [Abstract] [PDF]

				J. Nussberger, G. Wuerzner, C. Jensen, and H. R. Brunner Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril Hypertension, January 1, 2002; e8(1): . [Abstract] [Full Text] [PDF]

				M. A. Weber, R. L. Byyny, J. H. Pratt, E. P. Faison, D. B. Snavely, A. I. Goldberg, and E. B. Nelson Blood Pressure Effects of the Angiotensin II Receptor Blocker, Losartan Arch Intern Med, February 27, 1995; 155(4): 405 - 411. [Abstract] [PDF]

				J. Menard, R. S. Boger, D. M. Moyse, T. T. Guyene, H. N. Glassman, and H. D. Kleinert Dose-Dependent Effects of the Renin Inhibitor Zankiren HCl After a Single Oral Dose in Mildly Sodium-Depleted Normotensive Subjects Circulation, January 15, 1995; 91(2): 330 - 338. [Abstract] [Full Text]